Overview

A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

Status:
Completed

Trial end date:
2017-02-10

Target enrollment:

Participant gender:

Summary

This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors (NSAIs) in the adjuvant setting and symptoms of vaginal atrophy.

Phase:

Phase 2

Details

Lead Sponsor:

ITF Research Pharma, S.L.U.

Collaborator:

Spanish Breast Cancer Research Group

Treatments:

Aromatase Inhibitors
Hormones